NeuroSigma
is a medical device company that develops and markets eTNS systems for the treatment of Attention Deficit Hyperactivity Disorder... Read moreNeuroSigma
is a medical device company that develops and markets eTNS systems for the treatment of Attention Deficit Hyperactivity Disorder... Read more
News
Dec 15, 2025
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS Device
Nov 19, 2025
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
Nov 03, 2025
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
Jun 10, 2025
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
Jan 22, 2025
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
Dec 11, 2024
GlobalNewswire
Press Release: NeuroSigma : New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark's Center for Evidence-Based Psychiatry
May 09, 2024
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
Jan 18, 2024
Medical Product Outsourcing
NeuroSigma: NeuroSigma's Monarch 2.0 eTNS OK'ed for Pediatric ADHD
Nov 07, 2023
CityLife
NeuroSigma: NeuroSigma Submits FDA Application for Next-Generation Monarch eTNS System
Oct 03, 2023
GlobalNewswire
Press Release: NeuroSigma : NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
NeuroSigma Competitors
1
2
3
4
5
6
7
8
9
10